Factors associated with poor B-cell reconstitution (IVIG requirement) at 2 years post-HCT
| Variable . | OR (95% CI) . | P* . | aOR (95% CI) . | P* . |
|---|---|---|---|---|
| Molecular diagnosis (ARTEMIS) | 4.4 (2.8-6.9) | <.0001 | 4.8 (2.5-9.3) | <.0001 |
| Native American† | 6.6 4.5-9.6) | <.0001 | ||
| Ulcers | 2.2 (1.0-4.8) | .04 | ||
| Conditioning | <.0001 | |||
| None or immunosuppression only‡ | 1 | |||
| Low-dose busulfan (8 mg/kg§) | 0.1 (0.0-0.5) | .007 | ||
| Myeloablative|| | 0.3 (0.1-1.2) | .09 | ||
| Any alkylator therapy¶ | 0.4 (0.2-1.0) | .04 | 0.3 (0.1-1.0) | .04 |
| Haploidentical donor | 1.2 (0.4-3.2) | .8 | 2.1 (1.3-3.4) | .03 |
| No myeloid chimerism (recipient) | 10.0 (1.7-60.6) | .001 | ||
| Retransplantation | 4.7 (1.6-13.8) | .005 | ||
| Boost | 4.2 (0.9-10.0) | .07 | ||
| Additional procedure (re-HCT, boost) | 3.3 (0.8-14.2) | .1 | 5.2 (2.0-14.0) | .001 |
| CD4+ T cells at 2 y post-HCT (≤600 cells/mm3) | 4.7 (1.5-15.0) | .01 | 6.6 (2.3-19.0) | <.0001 |
| Variable . | OR (95% CI) . | P* . | aOR (95% CI) . | P* . |
|---|---|---|---|---|
| Molecular diagnosis (ARTEMIS) | 4.4 (2.8-6.9) | <.0001 | 4.8 (2.5-9.3) | <.0001 |
| Native American† | 6.6 4.5-9.6) | <.0001 | ||
| Ulcers | 2.2 (1.0-4.8) | .04 | ||
| Conditioning | <.0001 | |||
| None or immunosuppression only‡ | 1 | |||
| Low-dose busulfan (8 mg/kg§) | 0.1 (0.0-0.5) | .007 | ||
| Myeloablative|| | 0.3 (0.1-1.2) | .09 | ||
| Any alkylator therapy¶ | 0.4 (0.2-1.0) | .04 | 0.3 (0.1-1.0) | .04 |
| Haploidentical donor | 1.2 (0.4-3.2) | .8 | 2.1 (1.3-3.4) | .03 |
| No myeloid chimerism (recipient) | 10.0 (1.7-60.6) | .001 | ||
| Retransplantation | 4.7 (1.6-13.8) | .005 | ||
| Boost | 4.2 (0.9-10.0) | .07 | ||
| Additional procedure (re-HCT, boost) | 3.3 (0.8-14.2) | .1 | 5.2 (2.0-14.0) | .001 |
| CD4+ T cells at 2 y post-HCT (≤600 cells/mm3) | 4.7 (1.5-15.0) | .01 | 6.6 (2.3-19.0) | <.0001 |
n = 76 patients (still alive >2 y post-HCT). Patients were clustered using a group variable to take into account the practice variations between centers.
aOR, adjusted odds ratio.
P values are referring to univariate analysis (left column) and multivariate analysis (right column), respectively. Only significant results in univariate analysis are shown.
Variable not kept in the multivariate model because of colinearity with ulcers.
Serotherapy with antithymocyte globulin (ATG) or Campath, cyclophosphamide only, or cyclophosphamide in combination with nonmyeloablative irradiation.
Associated with cyclophosphamide.
Busulfan 16 mg/kg associated with cyclophosphamide or fludarabine.
Category analyzing all conditioning regimens containing the following alkylating agents including both immunosuppressive and stem cell–toxic regimens: busulfan, treosulfan, thiothepa, melphalan, cyclophosphamide.